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Background: Recombinant human B-type natriuretic peptide (rhBNP) has been indicated for the treatment of acute
decompensated heart failure (ADHF). However, the therapeutic efficacy of intravenous rhBNP is not always satisfactory in
patients with extremely high blood BNP levels. In this study, we evaluated the effects of rhBNP on patients with different
BNP levels.
Methods: One hundred and five patients with ADHF whose left ventricular ejection fraction (LVEF) was <40%, were
assigned to a high BNP group (BNP≤ 3000 pg/mL) or an extra-high BNP group (BNP > 3000 pg/mL) , depending on
their admission plasma BNP levels. Each group was then subdivided into rhBNP or dobutamine subgroups according to
intravenous administration with either rhBNP or dobutamine for 24-72h. In the high BNP group, 58 patients were
randomized to subgroup rhBNP (n = 28) and subgroup dobutamine (n = 30). In the extra-high BNP group, 47 patients
were randomized to subgroup rhBNP (n = 24) and subgroup dobutamine (n = 23). The effects of rhBNP and dobutamine
on patients in the high and extra-high BNP groups were compared.
Results: In the high BNP group, rhBNP was more efficient than dobutamine at improving NYHA classification (P < 0.05),
decreasing plasma BNP levels (P < 0.05), increasing LVEF (P < 0.05), and reducing hospital length of stay (P < 0.05).
However, rhBNP displayed no superior therapeutic efficacy to dobutamine in the extra-high BNP group. Adverse
cardiovascular events in patients treated with rhBNP were similar to adverse events in patients treated with dobutamine
in both the high and extra-high BNP groups.
Conclusions: rhBNP was more efficient than dobutamine at improving heart function in patients with ADHF when
plasma BNP was ≤3000 pg/mL. However, rhBNP treatment showed no advantages over dobutamine when plasma BNP
reached extremely high levels (>3000 pg/mL).
Trial registration: ClinicalTrials.gov Identifier: NCT01837849.
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Acute decompensated heart failure (ADHF) is associated
with significant morbidity and mortality and remains a
common cause of hospitalization worldwide. As a result,
therapies targeting both symptoms and cardiovascular
outcomes are greatly needed. Two such treatments are* Correspondence: dr.zhujianhua@gmail.com
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Dobutamine is a synthetic catecholamine that acts
mainly through stimulation of β1-receptors and partly
through β2-receptors to produce dose-dependent posi-
tive inotropic and chronotropic effects [1]. It has long
been used as a potent positive inotrope for the manage-
ment of severe heart failure. rhBNP is a recombinant
formulation of BNP that is identical to the endogenous
hormone released from the cardiac ventricle in response. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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overload [2]. It is a potent vasodilator that is proven to
rapidly reduce cardiac filling pressures and improve dys-
pnea in patients with ADHF [3]. In 2005, rhBNP was
recommended in the ADHF treatment guidelines by the
European Society of Cardiology [4].
Some evidence suggests that rhBNP is more effective
than dobutamine in the treatment of heart failure [5-7].
However, in our clinical work, we have found that the
effects of rhBNP are not always satisfactory in patients
with extremely high blood BNP levels, with the heart
function of some patients not improved until rhBNP is re-
placed by dobutamine. Although comparison of rhBNP
and dobutamine in ADHF patients has been reported in
several studies [5-7], no comparative study has been per-
formed on ADHF patients with different plasma BNP
levels. Thus, the purpose of this study was to determine
the therapeutic efficacy of rhBNP in ADHF patients with
different plasma BNP levels in comparison to that of dobu-
tamine in order to provide valuable information for the
treatment of heart failure.
Methods
Patient selection
Between January 2011 and June 2012, patients with
ADHF who required hospitalization were enrolled in the
study. The mean age was 66 ± 13 years (range = 29–88).
The ADHF etiology included idiopathic dilated cardio-
myopathy (IDC), coronary heart disease (CHD), fulmin-
ant viral myocarditis (FVM), hyperthyroid heart disease
(HHD), and valvulopathy. All patients were classified as
New York Heart Association (NYHA) class III–IV and
had an ejection fraction of <40%. Exclusion criteria
included intravenous administration with rhBNP or do-
butamine in the 2 weeks before study entry, acute
myocardial infarction, significant valvular stenosis, ser-
ious ventricular arrhythmia (frequent ventricular prema-
ture beat of >5 bpm, nonsustained and sustained
ventricular tachycardia), blood pressure <95/60 mmHg
or >140/90 mmHg, shock, hypovolemia, and hepatic or
renal impairment [alanine aminotransferase or aspartate
aminotransferase >2 times the upper limit of the normal
value, serum creatinine >177 μmol/L (2.0 mg/dl) for man
or >146 μmol/L (1.7 mg/dl) for women]. In addition, preg-
nant and lactating women, those who had to change
medication due to adverse events during the study
were also excluded. All patients provided informed
consent, and the Ethics Committee of Affiliated Hospital
of Nantong University approved the protocol.
Study design
Previous studies evaluating the correlation between BNP
level and heart failure severity used 3000 pg/mL as the
cut-off for extremely high BNP elevation [8,9]. In thisopen-label prospective cohort study we also used value
of 3000 pg/mL (30 times the upper normal range) as the
cut-off for stratifying patients into high and extra BNP
groups. Enrolled patients were stratified into a high BNP
group (BNP ≤ 3000 pg/mL) or extra-high BNP group
(BNP > 3000 pg/mL) depending on their admission
plasma BNP levels. Each group was then subdivided
into two subgroups (rhBNP or dobutamine) according to
the intravenous administration of either rhBNP or dobu-
tamine. Patients in the high and extra-high BNP groups
were randomly assigned to rhBNP or dobutamine sub-
groups using a computer-generated random number
table. In total, 58 patients were enrolled in the high BNP
group, of which 28 were randomized to the rhBNP
subgroup and 30 were randomized to the dobutamine
subgroup. In addition, 47 patients were enrolled in the
extra-high BNP group, of which 24 were randomized to
the rhBNP subgroup and 23 were randomized to the do-
butamine subgroup.
Procedure
In addition to conventional heart failure therapy, pa-
tients in the rhBNP and dobutamine subgroups received
rhBNP (marketed as Xinhuosu, Chengdu Rhodiola Bio-
Pharmacy, Chengdu, China) and dobutamine (Shanghai
No. 1 Biochemical & Pharmaceutical, Shanghai, China)
infusion, respectively, for a period of 24–72 h. rhBNP
was administered as an intravenous bolus of 1.5 μg/kg
followed by continuous infusion in doses of 0.0075–
0.01 μg/kg/min according to each patient’s clinical
status. Patients in the dobutamine subgroup initially
received 2.5 μg/kg/min dobutamine and were up-
titrated to 10 μg/kg/min if hemodynamic goals were not
achieved.
Plasma creatinine and BNP levels were measured at
baseline and 5 days after the start of the study. Creatin-
ine was detected by a creatinine assay kit (Abcam, MA,
USA). BNP levels were determined with the ARCHITECT
BNP Reagent Kit (Abbott Laboratories, IL, USA). Left ven-
tricle end diastolic dimension (LVEDD) and left ventricular
ejection fraction (LVEF) were measured by one observer
blinded to the clinical data with a GE Vivid E9 ultrasound
scanner (GE Healthcare, Horten, Norway) at the time of
blood sample drawing.
Assessment of efficacy
The drug therapeutic efficacy was assessed as improve-
ment of functional class; changes in BNP levels, LVEDD,
and LVEF from baseline to fifth day after the beginning
of treatment. According to the assessed dyspnea and sys-
temic symptoms, the functional improvement was graded
as “excellent” (NYHA class was improved ≥2 functional
classes), “improved” (NYHA class was improved 1 func-
tional class) or “failed” (NYHA class remained the same or
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(patients with “excellent” + patients with “improved”/all
patients) × 100%.
In addition, the length of hospitalization and the effects
of the study drugs on blood pressure, heart rate (HR),
blood creatinine, and cardiovascular adverse events during
infusion were also analyzed.
Statistical analysis
Statistical analysis was performed with SigmaStat 3.5
(Systat Software, Point Richmond, CA, USA) statistical
software. Quantitative data are presented as mean ±
standard deviation (SD), while categorical data are pre-
sented as numbers. Comparisons between the two
groups were made using a two-sample t-test for continu-
ous variables and chi-squared test or Fishe exact test for
categorical data. Differences between baseline and treat-




In the extra-high BNP group, one patient who was
assigned to the rhBNP subgroup had to withdraw from
the study because of symptomatic hypotension 3 h after
rhBNP administration; thus, 23 patients in the rhBNP
subgroup finished this study. Basal blood pressure and
plasma creatinine and baseline demographics and med-
ical history information for patients in the high and
extra-high BNP groups are summarized. Basal SBP level
tended to be lower in the extra-high BNP group than in
the high BNP group (P = 0.079), while plasma creatinine
was significantly higher in the extra-high BNP group
(P < 0.01) (Table 1). However, the baseline character-
istics of the patients and heart failure medications in
patients randomized to the rhBNP subgroup or the dobu-
tamine subgroup were well balanced in both the high and
extra-high BNP groups (Table 2).
Changes in NYHA class
Functional improvements, as assessed by NYHA class,
were observed so as to evaluate the therapeutic efficacyTable 1 Baseline blood pressure and plasma creatinine in
the high and Extra-high BNP groups
Parameters High-BNP group Extra-high BNP group P value*
(n = 58) (n = 46)
SBP (mmHg) 121.0 ± 12.3 116.7 ± 12.5 0.079
DBP (mmHg) 72.9 ± 7.2 71.3 ± 6.5 0.229
Cr (μmol/L) 81.6 ± 30.7 97.0 ± 27.1 0.009
*Unpaired t test.
Abbreviations: BNP brain natriuretic peptide, Cr creatinine, DBP diastolic blood
pressure, SBP systolic blood pressure.of the treatments. Both rhBNP and dobutamine could
effectively improve patient cardiac function. In the high
BNP group, rhBNP was significantly more efficacious
than dobutamine in improving NYHA class. The pro-
portion of patients showing a functional improvement of
at least 1 grade in NYHA class was significantly greater
in the rhBNP subgroup (92.86%, 26/28) than in the do-
butamine subgroup (70%, 21/30) (P < 0.05). However, in
the extra-high BNP group, the overall effective rates of
the two subgroups did not differ significantly [56.52%
(13/23) vs. 65.22 (15/23) (P > 0.05)] (Table 3).
Changes in blood BNP, LVEDD and LVEF in the high
BNP group
Changes in blood BNP, LVEDD, and LVEF were analyzed
to assess the therapeutic efficacy. In the high BNP group,
both rhBNP and dobutamine were able to significantly
reduce the plasma BNP levels (P < 0.01), decrease LVEDD
(P < 0.01), and increase LVEF (P < 0.01). Compared to
dobutamine, rhBNP was significantly more efficacious
in reducing plasma BNP (P < 0.05) and increasing LVEF
(P < 0.05), but the decrease of LVEDD in the rhBNP sub-
group was similar to that of the dobutamine subgroup
(P > 0.05) (Table 4).
Changes in blood BNP, LVEDD and LVEF in the extra-high
BNP group
The measurement range for the ARCHITECT BNP
assay is 10–5000 pg/mL. In the extra-high BNP group,
there were 10 patients (6 from the dobutamine sub-
group and 4 from the rhBNP subgroup) whose plasma
BNP levels were >5000 pg/mL before the study; there-
fore, as we only selected patients with plasma BNP
levels ≤5000 pg/mL for statistical analyses of BNP
changes, their BNP levels could not be used for cal-
culating the mean BNP values. Nonetheless, the changes in
LVEDD and LVEF were still analyzed in all enrolled pa-
tients. Of the 10 patients with plasma BNP >5000 pg/mL,
there were 5 and 3 patients in the dobutamine and
rhBNP subgroups, respectively, whose plasma BNP
levels were reduced to <5000 pg/mL. The average
plasma BNP level in the rhBNP subgroup was slightly,
but not significantly, higher than that of the dobuta-
mine subgroup (4020 ± 710 pg/mL vs. 3508 ± 654 pg/mL;
P > 0.05) at day 5 after treatment. Similarly, the BNP
levels in patients with plasma BNP ≤ 5000 pg/mL was
effectively reduced by rhBNP and dobutamine (P < 0.01)
(Table 5). In addition, both rhBNP and dobutamine
slightly, but significantly decreased the LVEDD (P < 0.05),
and significantly increased the LVEF (P < 0.05) of all en-
rolled patients. The therapeutic efficacy of dobutamine in
improving these parameters tended to be better than that
of rhBNP, although the difference was not statistically sig-
nificant (P > 0.05) (Table 5).
Table 2 Baseline characteristics and treatment information










Age (y) 63 ± 13 65 ± 13 0.495† 68 ± 14 67 ± 12 0.709†
Male/female 19/11 18/10 0.843‡ 15/8 16/7 0.935‡
HF etiology
IDC 13 11 0.963‡ 10 12 0.768‡
CHD 8 10 0.645‡ 10 8 0.763‡
FVM 2 1 1.000§ 0 1 1.000§
HHD 1 2 0.605§ 0 1 1.000§
Valvulopathy 6 4 0.732§ 3 1 0.608§
NHYA 0.645‡ 0.489§
III 8 10 0 2
IV 22 18 23 21
Concomitant medications
ACEI 14 16 0.593‡ 14 12 0.766‡
ARB 12 7 0.349‡ 5 8 0.513‡
Digitalis 24 23 0.899‡ 18 20 0.699§
β-blockers 11 14 0.448‡ 4 6 0.722§
Spironolactone
20 (mg/d) 15 18 0.405‡ 11 6 0.324‡
40 (mg/d) 10 8 0.914‡ 10 12 0.768‡
Average dosage 28.0 ± 10.0 26.2 ± 9.4 0.500† 29.5 ± 10.2 33.3 ± 9.7 0.243†
Furosemide (mg/d)
20 (mg/d) 12 15 0.440‡ 7 4 0.328§
40 (mg/d) 11 8 0.707‡ 11 9 0.766‡
80 (mg/d) 2 3 0.665§ 3 5 0.699§
Average dosage 33.6 ± 17.0 33.1 ± 19.5 0.919† 39.0 ± 19.5 46.7 ± 22.8 0.267†
†Unpaired t-test; ‡Chi-square test; §Fisher exact test.
Abbreviations: ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, BNP brain natriuretic peptide, CHD coronary heart disease, HF
heart failure, HHD hyperthyroid heart disease, IDC idiopathic dilated cardiomyopathy, NHYA New York Heart Association, rhBNP recombinant human brain natriuretic
peptide. Values are expressed as number or mean ± SD.
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No patients died during administration of dobutamine
or rhBNP. One patient with dilated cardiomyopathy in
the extra-high BNP group whose symptoms were much
improved by dobutamine suffered sudden death due to
ventricular fibrillation at 8 days after withdrawal of do-
butamine infusion during hospitalization; we excluded
this patient from analysis of hospitalization length. InTable 3 Changes in NYHA class from baseline to day 5 after t
Groups Dobutamine
Total Ex Im Fa OER
High BNP 30 12 9 9 21 (7
Extra-high BNP 23 6 9 8 15 (6
Abbreviations: Ex Excellent, Fa failed, Im improved, OER overall effective rate. Other abbrethe high BNP group, length of hospitalization for rhBNP-
treated patients was significantly shorter than for patients
treated with dobutamine (8.0 ± 1.9 versus 9.3 ± 2.2 days,
P < 0.05). However, in the extra-high BNP group, the
length of hospitalization was not significantly different
between the two subgroups (13.0 ± 3.1 versus 12.2 ±
2.7 days, P > 0.05). All-cause mortality during hospi-
talization was similar between the dobutamine and rhBNPreatment
rhBNP
(%) Total Ex Im Fa OER (%)
0.00) 28 9 17* 2 26 (92.86)*
5.22) 23 5 8 10 13 (56.52)
viations are same as in Table 2. *P < 0.05 versus (Fisher exact test) dobutamine.
Table 4 Changes in blood BNP, LVEDD, and LVEF in the high BNP group
Parameters Dobutamine (n = 30) rhBNP (n = 28)
Baseline 5 Days Changes Baseline 5 Days Changes
BNP (pg/mL) 1890 ± 742 1261 ± 560** 629 ± 715 1819 ± 665 843 ± 450**ΔΔ 976 ± 566Δ
LVEDD (mm) 63.8 ± 4.6 61.2 ± 6.5** 2.6 ± 4.3 64.3 ± 4.9 60.9 ± 5.7** 3.3 ± 3.2
LVEF (%) 32.1 ± 6.1 39.6 ± 10.9** 7.5 ± 8.1 31.3 ± 6.8 43.7 ± 11.2** 12.4 ± 7.5Δ
Abbreviations: LVEDD left ventricle end diastolic dimension, LVEF left ventricular ejection fraction, Other abbreviations are same as in Table 2. Values are mean ± SD.
**P < 0.01 (paired t- test) versus baseline; ΔP < 0.05, ΔΔP < 0.01 (unpaired t- test) versus dobutamine.
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P = 1.000).
Effects of the study drugs on blood pressure, HR and
plasma creatinine
Ambulatory changes in systolic blood pressure (SBP),
diastolic blood pressure (DBP), and HR were monitored
during infusion. The SBP, DBP, and HR values at the end
of infusion and the levels of plasma creatinine at day 5
after treatment were measured. Both rhBNP and dobuta-
mine did not significantly affect HR and plasma creatin-
ine (P > 0.05). The systolic and diastolic pressure were
significantly decreased by rhBNP (P < 0.01), while no sig-
nificant changes were observed in dobutamine-treated
patients (P > 0.05) (Table 6).
Cardiovascular adverse events
The incidence of selected cardiovascular adverse events
during administration was similar between the rhBNP-
and dobutamine-treated patients. However, symptomatic
hypotension tended to be more common in the rhBNP-
treated patients than the dobutamine-treated patients,
although the difference was not statistically significant
(Table 7). In the extra-high BNP group, one patient who
was initially enrolled to the rhBNP subgroup had to with-
draw from this study due to symptomatic hypotension. We
still included this patient in the statistical analysis of ad-
verse events.
Discussion
Our study is the first to compare the effects of rhBNP
and dobutamine on ADHF patients with different
plasma BNP levels. The results revealed that rhBNP was
not superior to the traditional inotropic agent dobuta-
mine at improving cardiac function in patients withTable 5 Changes in blood BNP, LVEDD, and LVEF in the extra
Parameters Dobutamine (n = 23)
Baseline 5 Days Chan
BNP (pg/mL) 3790 ± 740 2806 ± 859** 985 ±
LVEDD (mm) 66.6 ± 5.1 64.2 ± 5.1* 2.4 ±
LVEF (%) 24.4 ± 5.7 31.6 ± 6.9** 7.2 ±
Abbreviations are same as in Table 2 and Table 4. Values are mean ± SD. §n = 17, ※nextra-high BNP levels (>3000 pg/mL). On the contrary,
rhBNP-treated patients tended to be more likely to ex-
perience hypotension than dobutamine-treated patients.
Dobutamine, a dopamine derivative, produces positive
inotropic and chronotropic effects on myocardium mainly
through stimulation of β1-receptors and by causing a reflex
decrease in sympathetic tone [1,10,11]. At low doses, dobu-
tamine induces mild arterial vasodilatation, which aug-
ments stroke volume by reductions in afterload [4], and
has little influence on HR, blood pressure, and cardiovas-
cular adverse events.
BNP, a natriuretic peptide, is produced and released
from the ventricles in response to increased wall stretch
and tension [2]. It binds to the A-type natriuretic pep-
tide receptor that is present on the surface of vascular
smooth muscle and endothelial cells [2], resulting in ac-
tivation of guanylate cyclase and the subsequent accu-
mulation of intracellular cyclic GMP in target tissues
[12]. Cyclic GMP, as a second messenger, mediates natri-
uretic, diuretic and smooth muscle relaxant effects,
which lead to the therapeutic benefits of venous and arter-
ial vasodilation and decreases in preload and afterload,
resulting in increased cardiac output with improved dys-
pnea and systemic symptoms [12].
In addition, BNP also serves as a physiological antag-
onist of the renin-angiotensin-aldosterone system and
the sympathetic nervous system [13]. It inhibits renin-
aldosterone secretion, suppresses the sympathetic ner-
vous system, and antagonizes the action of antidiuretic
hormone in inducing antidiuresis, antinatriuresis, and
vasoconstriction, leading to a decrease in systemic vas-
cular resistance and cardiac pre- and afterload [4,14,15].
Thus, as a compensatory mechanism for heart failure,
circulating BNP levels strongly correlate with the sever-
ity of heart failure [16,17].-high BNP group
rhBNP (n = 23)
ges Baseline 5 Days Changes
931§ 3912 ± 726 3207 ± 900** 705 ± 884※
4.6 67.7 ± 5.4 65.6 ± 6.3* 2.1 ± 4.2
6.1 23.8 ± 5.6 29.0 ± 6.5** 5.2 ± 7.1
= 19. *P < 0.05, **P < 0.01 (paired t- test) versus baseline.
Table 6 Effects of the study drugs on blood pressure (mmHg), HR (bpm) and plasma creatinine (μmol/L)
Parameters High BNP group Extra-high BNP group
Dobutamine (n = 30) rhBNP (n = 28) Dobutamine (n = 23) rhBNP (n = 23)
Baseline 5 Days Baseline 5 Days Baseline 5 Days Baseline 5 Days
SBP 119.3 ± 12.7 121.3 ± 12.0 122.9 ± 11.9 115.4 ± 12.4** 114.8 ± 11.9 116.0 ± 12.5 118.6 ± 13.0 113.2 ± 13.2**
DBP 72.4 ± 6.8 74.3 ± 5.3 73.5 ± 7.7 69.6 ± 7.9** 70.7 ± 6.7 71.8 ± 6.6 71.9 ± 6.5 68.7 ± 6.6**
HR 77.6 ± 12.5 80.3 ± 13.1 81.8 ± 11.1 83.9 ± 11.5 83.2 ± 13.9 85.7 ± 13.0 82.3 ± 12.4 84.6 ± 9.3
Cr 84.4 ± 29.8 79.3 ± 20.4 78.5 ± 31.9 80.9 ± 26.3 95.4 ± 24.4 90.3 ± 23.3 98.6 ± 30.1 105.5 ± 32.9
Abbreviations: HR heart rate. Other abbreviations are same as in Table 1 and Table 2. Values are mean ± SD. **P < 0.01 (paired t- test) versus baseline.
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biological activity as endogenous BNP, with a mean
terminal elimination half-life of 18–20 min [18,19],
which means that it is almost completely cleared at 3 h
post infusion withdrawal (approximately 9–10 elimin-
ation half-lives). Several studies indicated that BNP
changes during the first 5 days of hospitalization had a
very high prognostic value in patients with heart failure
[20,21]. Accordingly, we assayed the plasma BNP levels
at day 5 after treatment to evaluate the efficacy of
rhBNP and dobutamine. At this time, the exogenous
rhBNP had been completely eliminated and did not inter-
fere with the measurement of the endogenous BNP level,
allowing accurate assessment of the therapeutic efficacy of
the study drugs.
Numerous studies reported that BNP levels reflect
heart failure severity [16,17,22]. However, Law et al.
found that extremely high BNP level ( > 3000pg/mL) did
not correlate with heart failure severity when patients
had complications such as neurological disorder, sepsis,
or subarachnoid hemorrhage. The possible reasons
might be that in these patients, an increase in sympa-
thetic stimulation causes the hypothalamus to secrete
excess vasopressin and BNP [9,23]. In our study, all pa-
tients with these confounders were excluded. Thus, BNP
level might well reflect the status of heart function.Table 7 Selected cardiovascular adverse events during drug a
Adverse events High BNP group
Dobutamine (n = 30) rhBNP (n = 28)
Symptomatic hypotension 0 0
Asymptomatic hypotension 0 2
Sustained VT 0 0
Nonsustained VT 2 0
VF 0 0
Sudden death 0 0
Cardiac arrest 0 0
Abbrevations: VF ventricular fibrillation, VT ventricular tachycardia, Other abbreviatioWe found that rhBNP was more efficient than dobuta-
mine at improving heart function in patients with BNP
levels ≤3000 pg/mL. However, their efficacies were simi-
lar in patients with extra-high BNP levels. The difference
might be explained by the following reasons. First, BNP
exerts its biological activities through binding to the A-
type natriuretic peptide receptor, which is present on the
surface of vascular smooth muscle and endothelial cells
[2]. When the compensatorily increased endogenous
BNP is not sufficient to bind to all the free receptors,
the introduced exogenous BNP (rhBNP) can fully acti-
vate the remaining free receptors, resulting in a marked
improvement in heart function. However, when the cir-
culating BNP increases to even greater levels, with sub-
sequent full activation of their receptors, an insufficient
number of free BNP receptors can be bound by exogen-
ous BNP, meaning that the additional effects of exogen-
ous BNP on decreasing cardiac pre- and afterload are
inhibited. Second, patients with extremely high BNP
levels might be resistant to the biological action of BNP.
This phenomenon is characterized by extremely high
circulating BNP levels in patients with congestive heart
failure who have physical signs of fluid retention and
vasoconstriction from poor biological activity of the BNP
system [14]. A deficient response to BNP is attributed
to inactivation of BNP by plasma and tissue proteasesdministration
Extra-high BNP group
P value Dobutamine (n = 23) rhBNP (n = 24) P value
1.000 0 1 1.000
0.229 0 3 0.234
1.000 0 0 1.000
0.492 2 1 0.609
1.000 0 0 1.000
1.000 0 0 1.000
1.000 0 0 1.000
ns are same as in Table 2. Fisher exact text was used.
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desensitization of BNP-specific receptors, and mecha-
nisms that counteract the biological effects of BNP at
postreceptor level [14]. Third, patients with extremely
high BNP levels usually suffer from more severe heart
failure, accompanied by serious renal congestion and low
renal blood flow [24], which could inhibit the effects of
rhBNP on renal vessel dilation, natriuresis, and diuresis,
but would not affect the positive inotropic effects of do-
butamine on myocardium. In this study, basal plasma
creatinine was significantly higher in the extra-high BNP
group, suggesting deterioration of renal function might
be responsible for the low efficiency of rhBNP in patients
with extremely high BNP. In addition, patients with more
severe heart failure usually also have lower arterial pres-
sure. The SBP level in the extra-high BNP group tended
to be lower than in the high BNP group, although the dif-
ference was not significant (P = 0.079). Vasodilator drugs
such as rhBNP might lead to more satisfactory clinical
improvements in heart failure patients with high-normal
blood pressure.
The blood pressure in the rhBNP subgroup was de-
creased after treatment (Table 6). One patient in the
extra-high BNP group with low baseline blood pressure
(96/64 mmHg) experienced symptomatic hypotension
(84/50 mmHg) at 3 h after rhBNP infusion and had to
withdraw from the study. Plasma creatinine remained
unchanged in patients with plasma BNP ≤3000 pg/mL
after treatment, but it tended to increase in patients with
extra-high BNP levels after rhBNP treatment (Table 6).
One male patient in the extra-high BNP group who
received rhBNP had an increase in plasma creatinine
from 165 μmol/L (1.9 mg/dl, baseline) to 243 μmol/L
(2.7 mg/dl). These results indicate that rhBNP, as an an-
tagonist of the renin-angiotensin-aldosterone system
(RAAS), might impair renal function and induce azote-
mia in patients with severe heart failure whose renal
function depends on RAAS. Dobutamine had no obvious
effect on plasma creatinine.
Study limitations
The results of this study are limited by its open-label
design and the relatively small number of patients in
each subgroup. Moreover, the effects of rhBNP and
dobutamine on hospital readmissions and long-term
survival were not assessed. More information from a
larger blinded study will be required to confirm the
results of this study.
Conclusions
We found that rhBNP was more efficient than dobutamine
in ADHF patients who had plasma BNP ≤3000 pg/mL.
However, rhBNP therapy was not superior to dobutamine
when BNP reached extremely high level (>3000 pg/mL).Abbreviations
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